The Russian anti-COVID-19 vaccine Sputnik V was registered by the National Directorate of Pharmaceuticals and Medicines of the Republic of Guinea and the Ministry of Health of Tunisia, the Russian Direct Investment Fund (RDIF) reports.
The Republic of Guinea and Tunisia, respectively, became the second and third countries in Africa, approved the use of the Russian Sputnik V vaccine. In both states, the drug is registered as part of an accelerated procedure (emergency use authorization) based on data from clinical studies conducted in Russia.
According to Kirill Dmitriev, CEO of the RDIF, Guinean President Alfa Condé has already been vaccinated with a Russian drug.
The Sputnik V vaccine, in addition to Russia, Guinea and Tunisia, is also registered in Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary and the UAE.
The effectiveness of the Sputnik V vaccine is above 90%, the vaccine, according to researchers, provides full protection against severe cases of coronavirus. It is created on a well-studied platform of human adenoviral vectors. The vaccine uses two different vectors for the two injections in the vaccination process, which forms more robust immunity compared to vaccines that use the same delivery mechanism for both injections.
